Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action

Darren J. Creek, Hwa H. Chua, Simon A. Cobbold, Brunda Nijagal, James I. MacRae, Benjamin K. Dickerman, Paul R. Gilson, Stuart A. Ralph, Malcolm J. McConville

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Abstract

High-throughput phenotypic screening of chemical libraries has resulted in the identification of thousands of compounds with potent antimalarial activity, although in most cases, the mechanism(s) of action of these compounds remains unknown. Here we have investigated the mode of action of 90 antimalarial compounds derived from the Malaria Box collection using high-coverage, untargeted metabolomics analysis. Approximately half of the tested compounds induced significant metabolic perturbations in in vitro cultures of Plasmodium falciparum. In most cases, the metabolic profiles were highly correlated with known antimalarials, in particular artemisinin, the 4-aminoquinolines, or atovaquone. Select Malaria Box compounds also induced changes in intermediates in essential metabolic pathways, such as isoprenoid biosynthesis (i.e., 2-C-methyl-D-erythritol 2,4-cyclodiphosphate) and linolenic acid metabolism (i.e., traumatic acid). This study provides a comprehensive database of the metabolic perturbations induced by chemically diverse inhibitors and highlights the utility of metabolomics for triaging new lead compounds and defining specific modes of action, which will assist with the development and optimization of new antimalarial drugs.

Original languageEnglish
Pages (from-to)6650-6663
Number of pages14
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number11
DOIs
Publication statusPublished - 1 Nov 2016

Cite this